INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 63 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $218 | -22.4% | 6,900 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $281 | -53.4% | 6,900 | -57.4% | 0.00% | 0.0% |
Q1 2023 | $603 | +27.2% | 16,200 | +19.1% | 0.00% | -50.0% |
Q4 2022 | $474 | -99.9% | 13,600 | -14.5% | 0.00% | -50.0% |
Q3 2022 | $889,000 | +8.2% | 15,900 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $822,000 | -24.6% | 15,900 | +6.0% | 0.00% | 0.0% |
Q1 2022 | $1,090,000 | -40.9% | 15,000 | -3.8% | 0.00% | -33.3% |
Q4 2021 | $1,844,000 | -19.1% | 15,600 | -8.2% | 0.01% | -33.3% |
Q3 2021 | $2,280,000 | -13.6% | 17,000 | +4.3% | 0.01% | 0.0% |
Q2 2021 | $2,639,000 | +147.3% | 16,300 | +22.6% | 0.01% | +125.0% |
Q1 2021 | $1,067,000 | +80.2% | 13,300 | +22.0% | 0.00% | +100.0% |
Q4 2020 | $592,000 | – | 10,900 | – | 0.00% | – |
Q1 2017 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
Q4 2016 | $41,000 | -24.1% | 3,200 | 0.0% | 0.00% | – |
Q3 2016 | $54,000 | +10.2% | 3,200 | +39.1% | 0.00% | – |
Q2 2016 | $49,000 | – | 2,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 744,160 | $54,078,000 | 5.79% |
Discovery Value Fund | 986,173 | $71,665,000 | 5.28% |
Ally Bridge Group (NY) LLC | 60,000 | $4,360,000 | 3.23% |
MPM BioImpact LLC | 159,409 | $11,584,000 | 3.11% |
ARK Investment Management | 8,981,029 | $652,651,000 | 2.72% |
Elmwood Wealth Management, Inc. | 67,599 | $4,912,000 | 2.52% |
Nikko Asset Management Americas, Inc. | 2,872,269 | $192,442,000 | 1.41% |
Frazier Life Sciences Management, L.P. | 203,684 | $14,802,000 | 1.26% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $8,098,000 | 1.22% |
Merlin Capital, Inc | 11,575 | $841,000 | 1.11% |